CK 0045
Alternative Names: CK-0045Latest Information Update: 15 Jan 2024
At a glance
- Originator Novo Nordisk
- Developer Cytoki Pharma
- Class Anti-inflammatories
- Mechanism of Action Interleukin-22 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 04 Jan 2024 Cytoki Pharma completes a phase I trial in Inflammatory bowel diseases in Belgium (SC) (NCT05712876)
- 26 Dec 2022 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in Belgium (SC) (NCT05712876)
- 05 May 2021 Interleukin-22 therapeutics licenses to Cytoki Pharma, before May 2021